Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net loss	$ (22,930)	$ (12,828)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation, amortization, and impairment	139	207
Share-based compensation	1,587	1,580
Amortization of debt issuance costs and discounts	2,750	2,673
Other, net	46	32
Changes in operating assets and liabilities:
Trade and other receivables, net	(3,129)	147
Inventories	(1,154)	(965)
Prepaid expenses and other assets	423	(253)
Accounts payable	1,905	1,284
Accrued expenses and other liabilities	(2,776)	(1,873)
Deferred revenue	(261)	(388)
Net cash used for operating activities	(23,400)	(10,384)
Investing activities:
Capital expenditures	(135)	(29)
Net cash used for investing activities	(135)	(29)
Financing activities:
Proceeds from exercise of stock options, net	0	539
Repayment of debt principal including lease liabilities	(6)	(5)
Payments for royalty obligations	(5)	0
Payments for taxes on share-based compensation	(703)	(893)
Net cash provided by financing activities	20,646	81,741
Net (decrease) increase in cash and cash equivalents	(2,889)	71,328
Cash and cash equivalents:
Cash and cash equivalents at beginning of period	71,546	23,872
Cash and cash equivalents at end of period	68,657	95,200
Supplemental disclosures of cash flow information:
Cash payments for interest	1,525	1,003
Costs associated with public equity offering in Accounts Payable	0	313
Costs associated with public equity offering-ATM in Accounts Payable	89	0
At-the-market offering
Financing activities:
Proceeds from common stock issued under public equity offering	21,360	11,974
Public Equity Offering
Financing activities:
Proceeds from common stock issued under public equity offering	$ 0	$ 70,126